Holen Sie sich die Stockscreener-App
152.89
4.29%
-6.85
Schlusskurs vom Vortag:
$159.74
Offen:
$158.19
24-Stunden-Volumen:
768.76K
Relative Volume:
0.89
Marktkapitalisierung:
$7.52B
Einnahmen:
$4.06B
Nettoeinkommen (Verlust:
$413.08M
KGV:
19.09
EPS:
8.01
Netto-Cashflow:
$560.48M
1W Leistung:
-6.77%
1M Leistung:
+0.09%
6M Leistung:
-10.38%
1J Leistung:
-21.32%
1-Tages-Spanne:
$152.89
$158.80
1-Wochen-Bereich:
$149.03
$167.50
52-Wochen-Spanne:
$91.86
$230.02
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Vergleichen Sie CRL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
152.89 | 7.54B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
479.46 | 179.95B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
190.05 | 137.90B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
641.14 | 51.04B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
123.24 | 35.19B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
187.22 | 31.26B | 15.70B | 1.24B | 2.01B | 6.91 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-09 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Charles River Laboratories International, Inc. (NYSE:CRL) Short Interest Up 37.9% in August - MarketBeat
Logan Capital Management Inc. Has $1.74 Million Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Cinctive Capital Management LP Reduces Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Laboratories International (CRL) Expands Oncology Partnerships With PICI and CHLA - simplywall.st
Charles River Laboratories International (NYSE:CRL) Shares Gap UpWhat's Next? - MarketBeat
Charles River Laboratories International, Inc. Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer - MarketScreener
Charles River Collaborates to Advance Novel Oncology Research & Development - Contract Pharma
Charles River Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer - Business Wire
Gotham Asset Management LLC Increases Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat
Transcript : Charles River Laboratories International, Inc. Presents at Baird Global Healthcare Conference 2025, Sep-10-2025 09 - MarketScreener
Dynamic Technology Lab Private Ltd Boosts Stake in Charles River Laboratories International, Inc. $CRL - MarketBeat
Eminence Capital LP Sells 192,018 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International, Inc. $CRL Shares Bought by Royal Bank of Canada - MarketBeat
A Closer Look at Charles River Laboratories (CRL) Valuation Following Key Cell Therapy Platform Enhancement - simplywall.st
Charles River Labs stock rating upgraded by Jefferies on DSA bookings improvement - Investing.com Canada
Jefferies rates IQVIA, Charles River as Buy, ICON as Hold - MSN
Jefferies rates IQVIA, Charles River as Buy, ICON as Hold (CRL) - Seeking Alpha
This Thomson Reuters Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Evaluating Charles River Laboratories (CRL) Valuation Following New Cell Therapy Tech Integration - Yahoo Finance
CRL Stock Rating Upgraded to 'Buy' by Jefferies | CRL Stock News - GuruFocus
Charles River Laboratories International, Inc.'s (NYSE:CRL) Low P/S No Reason For Excitement - simplywall.st
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences - BioSpace
Charles River Laboratories to Present at Baird and Morgan Stanle - GuruFocus
What are the risks of holding Charles River Laboratories International Inc.July 2025 Update & Weekly High Conviction Ideas - beatles.ru
Ariel Investments LLC Purchases 33,449 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Is Charles River Laboratories International Inc. backed by strong institutional buyingTreasury Yields & Fast Exit and Entry Strategy Plans - beatles.ru
Canada Pension Plan Investment Board Buys 102,000 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
The Manufacturers Life Insurance Company Decreases Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
What’s the recovery path for long term holders of Charles River Laboratories International Inc.Profit Target & Consistent Profit Alerts - Newser
Measuring Charles River Laboratories International Inc.’s beta against major indicesMarket Trend Report & Risk Adjusted Buy/Sell Alerts - Newser
Published on: 2025-09-06 02:17:51 - خودرو بانک
Can Charles River Laboratories International Inc. lead its sector in growthTrade Exit Report & Expert Curated Trade Ideas - خودرو بانک
What are analysts’ price targets for Charles River Laboratories International Inc.July 2025 Levels & Free Weekly Watchlist of Top Performers - خودرو بانک
Why is Charles River Laboratories International Inc. stock going upWeekly Trend Recap & Stock Market Timing Techniques - خودرو بانک
Is Charles River Laboratories International Inc. likely to announce a buybackPortfolio Return Summary & Real-Time Volume Analysis - خودرو بانک
Is Charles River Laboratories International Inc. exposed to currency risks2025 Volatility Report & AI Enhanced Market Trend Forecasts - خودرو بانک
Sentiment analysis tools applied to Charles River Laboratories International Inc.2025 Performance Recap & Risk Managed Trade Strategies - Newser
How to read the order book for Charles River Laboratories International Inc.Market Growth Review & AI Driven Price Forecasts - Newser
Using AI based signals to follow Charles River Laboratories International Inc.Weekly Profit Report & Expert Approved Momentum Trade Ideas - Newser
Risk adjusted return profile for Charles River Laboratories International Inc. analyzed2025 Market Sentiment & Daily Profit Focused Screening - Newser
Leading vs lagging indicators on Charles River Laboratories International Inc. performanceJuly 2025 Volume & Verified High Yield Trade Plans - Newser
Tools to assess Charles River Laboratories International Inc.’s risk profilePortfolio Growth Summary & Stepwise Trade Execution Plans - Newser
Zacks Research Has Negative Estimate for CRL Q3 Earnings - MarketBeat
Does Charles River Laboratories International Inc. stock have upside surprise potentialJuly 2025 Outlook & AI Powered Market Trend Analysis - خودرو بانک
Applying Wyckoff theory to Charles River Laboratories International Inc. stock2025 Market Trends & Weekly Market Pulse Updates - Newser
Charles River Laboratories International Inc. stock trendline breakdownRecession Risk & Consistent Growth Stock Picks - Newser
Stock Analysis | Charles River Laboratories International OutlookMixed Signals Amid Diverging Analyst Views - AInvest
Strategies to average down on Charles River Laboratories International Inc.Earnings Recap Summary & Community Supported Trade Ideas - Newser
Is it the Right Time to Add CRL Stock to Your Portfolio Now? - sharewise.com
Risk vs reward if holding onto Charles River Laboratories International Inc.Earnings Risk Report & Fast Gain Swing Alerts - Newser
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):